Study details
Enrolling now
A First-in-human Study of IMP1734 in Participants With Advanced Solid Tumors
Eikon Therapeutics
NCT IDNCT06253130ClinicalTrials.gov data as of Apr 2026
Phase
Phase 1/2
Target enrollment
70
Study length
about 3 years
Ages
18–89
Locations
23 sites in AR, AZ, CA +13
What this study is about
Researchers are testing a new medication called IMP1734 to see if it can help people with advanced solid tumors. The trial will last for about 1086 days and involve approximately 70 participants.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take IMP1734
Participation Burden
What's physically and logistically required of participants.
Logistics & Travel
In-person visits
Requires travel to a study site
Physical Intervention
Standard
How treatment is administered
Treatment Assignment
Standard assignment
Assignment is predetermined by the study protocol.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Endpoints
Primary: Number of subjects with adverse events, treatment emergent adverse events or serious adverse events
Secondary: Overall Response Rate, Pharmacokinetic parameters of IMP1734
Body systems
Oncology